癌症診療準則與核心測量 - 淋巴瘤 彰化基督教醫院內科部血液腫瘤科張正雄. Agenda
|
|
- Clifton Curtis
- 5 years ago
- Views:
Transcription
1 癌症診療準則與核心測量 - 淋巴瘤 彰化基督教醫院內科部血液腫瘤科張正雄 Agenda Lymphocyte differentiation Classification of lymphomas Disease definitions and symptoms Tests that identify specific lymphoid histologies Staging Cancer registry Treatment and prognosis Summary
2 Lymphocyte differentiation 3 Regenerative Medicine,
3 B-cell Differentiation B Antigen-Induced B-Cell Maturation Immature/transitional B cell Marginal-zone B cell Follicular B cell T-cell-independent antigen Outside germinal center V-gene mutation Not obligatory T-cell-dependent antigen Inside germinal center Obligatory Plasma cell Memory cell Plasma cell Memory cell With or without V-gene mutations V-gene mutations Image A provided courtesy of Stefano A. Pileri, MD Image B: Copyright 2005 Massachusetts Medical Society. All rights reserved. Chiorazzi N, et al. N Engl J Med. 2005;352: B cell Differentiation 6
4 T cell Differentiation 7 Major Types of B Cell Lymphoma Aggressive or high grade Indolent or low grade Lymphoplasmacytic NHL B-ALL subtypes Indolent B-CLL Mantle cell NHL Immunoblastic Burkitt Large B lymphoma Follicular center cells Small cleaved Marginal zone NHL B-CLL Myeloma
5 Classification of lymphomas 9 Historical Classification Systems for Non Hodgkin Lymphoma Working Formulation Low grade A. Small lymphocytic, consistent with chronic lymphocytic leukemia B. Follicular, predominantly smallcleaved cell C. Follicular, mixed small cleaved, and large cell Intermediate grade D. Follicular, predominantly large cell E. Diffuse, small cleaved cell F. Diffuse mixed, small and large cell G. Diffuse, large cell, cleaved, or noncleaved cell High grade H. Immunoblastic, large cell I. Lymphoblastic, convoluted, or nonconvoluted cell J. Small noncleaved cell, Burkitt, or non Burkitt Rappaport Classification Diffuse lymphocytic, well differentiated Nodular lymphocytic, poorly differentiated Nodular mixed, lymphocytic, and histiocytic Nodular histiocytic Diffuse lymphocytic, poorly differentiated Diffuse mixed, lymphocytic, and histiocytic Diffuse histiocytic Diffuse histiocytic Diffuse lymphoblastic Diffuse undifferentiated Burkitt or non Burkitt
6 Classification of Tumors 2008 WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, 4 th edition, October WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues Basic principle: Classification for all neoplasms based on: Morphology and biologic features Genetic Immunophenotype Clinical features 12
7 2008 WHO Classification Lymphoid Precursor Lymphoid Neoplasms Mature B Cell Neoplasms Mature T Cell and NK Cell Neoplasms Hodgkin Lymphoma Histiocytic and Dendritic Cell Neoplasms Post Transplant Lymphoproliferative Disorders 13 Precursor Lymphoid Neoplasms Table B7: Precursor Lymphoid Neoplasms WHO Preferred Term B lymphoblastic leukemia/lymphoma ICD-O-3 No Code B lymphoblastic leukemia/lymphoma with hyperdiploidy 9815/3 B lymphoblastic leukemia/lymphoma with hypodiploidy (hypodiploid ALL) 9816/3 B lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities No Code B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1) 9818/3 B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1) 9814/3 B lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32); IL3-IGH 9817/3 B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1 9812/3 B lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged 9813/3 B lymphoblastic leukemia/lymphoma, NOS 9811/3 T lymphoblastic leukemia/lymphoma 9837/3 14
8 Mature B Cell Neoplasms part I Table B8: Mature B-Cell Neoplasms WHO Preferred Term ICD-O-3 ALK positive large B-cell lymphoma 9737/3 B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell 9596/3 lymphoma and classical Hodgkin lymphoma B-cell prolymphocytic leukemia 9833/3 Burkitt lymphoma 9687/3 Chronic lymphocytic leukemia/small lymphocytic lymphoma 9823/3 Diffuse large B-cell lymphoma (DLBCL), NOS 9680/3 Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT 9699/3 lymphoma) Extraosseous plasmacytoma 9734/3 Follicular lymphoma 9690/3 Hairy cell leukemia 9940/3 Heavy chain disease 9762/3 Intravascular large B-cell lymphoma 9712/3 15 Mature B Cell Neoplasms part II WHO Preferred Term Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease ICD-O /3 Lymphomatoid granulomatosis 9766/1 Lymphoplasmacytic lymphoma 9671/3 Mantle cell lymphoma 9673/3 Plasma cell myeloma 9732/3 Plasmablastic lymphoma 9735/3 Primary cutaneous follicle centre lymphoma 9597/3 Primary effusion lymphoma 9678/3 Primary mediastinal (thymic) large B-cell lymphoma 9679/3 Solitary plasmacytoma of bone 9731/3 Splenic B-cell lymphoma/leukemia, unclassifiable 9591/3 Splenic marginal zone lymphoma 9689/3 T-cell/histiocyte rich large B-cell lymphoma 9688/3 16
9 Mature T Cell and NK Cell Neoplasms Table B9: Mature T-Cell and NK-Cell Neoplasm WHO Preferred Term ICD-O-3 Adult T-cell leukemia/lymphoma 9827/3 Aggressive NK-cell leukemia 9948/3 Anaplastic large cell lymphoma, ALK positive 9714/3 Angioimmunoblastic T-cell lymphoma 9705/3 Chronic lymphoproliferative disorder of NK-cells 9831/3 Enteropathy-associated T-cell lymphoma 9717/3 Extranodal NK/T cell lymphoma, nasal type 9719/3 Hepatosplenic T-cell lymphoma 9716/3 Hydroa vacciniforme-like lymphoma 9725/3 Lymphoimatoid papulosis 9718/3 Mycosis fungoides 9700/3 Peripheral T-cell lymphoma, NOS 9702/3 Primary cutaneous anaplastic large cell lymphoma 9718/3 Primary cutaneous CD30 positive T-cell lymphoproliferative disorders No Code Primary cutaneous CD4 positive small/medium cell T-cell lymphoma 9709/3 Primary cutaneous gamma-delta T-cell lymphoma 9726/3 Sezary syndrome 9701/3 Subcutaneous panniculitis-like T-cell lymphoma 9708/3 Systemic EBV positive T-cell lymphoproliferative disease of childhood 9724/3 17 T-cell prolymphocytic leukemia 9834/3 Hodgkin Lymphoma Table B10: Hodgkin Lymphoma WHO Preferred Term ICD-O-3 Classical Hodgkin lymphoma 9650/3 Lymphocyte-depleted classical Hodgkin lymphoma 9653/3 Lymphocyte-rich classical Hodgkin lymphoma 9651/3 Mixed cellularity classical Hodgkin lymphoma 9652/3 Nodular lymphocyte predominant Hodgkin lymphoma 9659/3 Nodular sclerosis classical Hodgkin lymphoma 9663/3 18
10 Histiocytic Cell and Dendritic Cell Neoplasms Table B11: Histiocytic and Dendritic Cell Neoplasm WHO Preferred Term Disseminated juvenile xsanthogranuloma ICD-O-3 No Code Fibroblastic reticular cell tumor 9759/3 Follicular dendritic cell sarcoma 9758/3 Histiocytic sarcoma 9755/3 Indeterminate dendritic cell tumor 9757/3 Langerhans cell histiocytosis 9751/3 Langerhans cell sarcoma 9756/3 19 Histiocytic Cell Neoplasms Table True histiocytic malignancy, a vanishing diagnosis. Original diagnosis Histiocytic lymphoma, nodular and diffuse Histiocytic medulary reticulosis Malignant histiocytosis Regressing atypical histiocytosis Intestinal malignant histiocytosis Histiocytic cytopathic panniculitis Currently considered Diffuse large B cell lymphoma Follicular lymphoma, grade 3 Peripheral T cell lymphoma Histiocyte rich variants of B cell, T cell, and Hodgkin lymphoma Anaplastic large cell lymphoma Haemophagocytic syndromes ALCL Haemophagocytic syndromes Primary cutaneous CD30 positive T cell lymphoma Enteropathy type T cell lymphoma Subcutaneous panniculitis like T cell lymphoma with Haemophagocytosis 20
11 Post Transplant Lymphoproliferative Disorders Table B12: Post-Transplant Lymphoproliferative Disorders (PTLD) WHO Preferred Term Early lesions ICD-O-3 No Code Classical Hodgkin lymphoma type PTLD * Infectious mononucleosis-like PTLD 9971/1 Monomorphic PTLD (B- and T/NK-cell types) * Plasmacytic hyperplasia 9971/1 Polymorphic PTLD 9971/3 *These lesions are classified according to the leukemia or lymphoma to which they correspond, and are assigned the respective ICD-O code. 21 Disease definitions and symptoms 22
12 Tumors Primary in Tissue Lymphoma: Malignant tumor in lymph nodes or lymphoid tissue Myeloid sarcoma: Solid tumor of immature white blood cells Plasma cell tumor (MM, extraosseous, osseous): Tumors comprised of plasma cells 23 Lymphoma Presentation Not specific to disease Swollen lymph nodes Chest pain/breathing problems Unexplained weight lost Recurring fevers/night sweats Rashes Lower back pain Sore LN after alcohol consumption 24
13 Tests That Identify Specific Lymphoid Histologies WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues Basic principle: Classification for all neoplasms based on: Morphology and biologic features Genetic Immunophenotype Clinical features 26
14 Genetic Testing Laboratory studies of blood, bone marrow, or tissue to analyze DNA to identify chromosome abnormalities which diagnose specific neoplasms 27 Normal Chromosomes 46 in each cell Each chromosome has a specific number Example: (1;2) Short arm p and a long arm q Example: (p13;q22) 28
15 Genetic Abnormalities 1. Translocation: t(1;2) 2. Inversion: inv16 3. Deletion: 7 or 7 4. Addition: +8 or Gene Translocation Courtesy: National Human Genome Research Institute 30
16 Gene Inversion Diego Diez, Ph, Bioinformatics Center, Institute for Chemical Research, Kyoto University. Gokasho, Uji, Kyoto JAPAN 31 Gene Deletion Courtesy: National Human Genome Research Institute 32
17 Gene Addition Walters L, Palmer JG. The Ethics of Human Gene Therapy. Oxford University Press Genetic Testing FISH: Identifies genetic changes and translocations. Polymerase chain reaction (PCR): Measures cancer cells that cannot be detected by FISH. Karyotyping: To arrange and classify chromosomes based on number, size, shape, and other characteristics. 34
18 FISH to Identify NPM/ALK Fusion Gene 35 Genetic Testing/Cytogenetics Appelbaum, MD, Frederick R. Leukemia [Internet]. Version 5. Knol Jul 28. Available from: 36
19 Karyotype 37 Immunophenotyping Cells from blood, BM, tissue used to determine types of antigens or markers on surface of cell. Referred to as CD CD; cluster of differentiation: Used to define the findings in immunophenotyping. 38
20 Additional Immunophenotyping Flow cytometry: Cells from blood, BM, tissue are treated with antibodies and passed in front of a laser beam. Immunocytochemistry (IHC): Shows specific antigens in cells from blood, BM, by using either fluorescent dyes or enzymes as markers 39 Immunohistochemistry 40
21 Staging 41 Stage Stage I Stage I NHL means involvement of a single lymph node region (I) or localized involvement of a single extralymphatic organ or site (IE). Stage II Stage II NHL means involvement of two or more lymph node regions on the same side of the diaphragm (II) or localized involvement of a single associated extralymphatic organ or site and its regional lymph nodes with or without other lymph node regions on the same side of the diaphragm (IIE). [Note: The number of lymph node regions involved may be indicated by a subscript (e.g., II3).]
22 Stage Stage III Stage III NHL means involvement of lymph node regions on both sides of the diaphragm (III) that may also be accompanied by localized involvement of an extralymphatic organ or site (IIIE), by involvement of the spleen (IIIS), or both (IIIS+E). Stage IV Stage IV NHL means disseminated (multifocal) involvement of one or more extralymphatic sites with or without associated lymph node involvement or isolated extralymphatic organ involvement with distant (nonregional) nodal involvement. Stage adult NHL can be subclassified into A and B categories : Afor those without such symptoms B for those with well defined generalized symptoms
23 B symptom B designation is given to patients with any of the following symptoms: I. Unexplained loss of more than 10% of body weight in the 6 months before diagnosis. II. Unexplained fever with temperatures above 38 C. III. Drenching night sweats. Stage I & II
24 Stage IIE & III Stage IV & Bone marrow aspiration
25 Stage I lymphoma PET Upstaged from stage II to stage IIIs
26 Stage IV lymphoma Cancer registry 52
27 Most Common Lymphomas T lymphoblastic: 2% Marginal zone, nodal: 2% Other: 9% Burkitt: 2% Anaplastic large cell: 2% Mediastinal large B cell: 2% Diffuse large B cell: 31% Mantle cell: 6% Small lymphocytic/cll: 7% Peripheral T cell: 7% Marginal zone, extranodal: 8% Follicular: 22% Armitage JO, et al. J Clin Oncol. 1998;16: USA New cases: 63,190. Deaths: 18,660. Cancer registry Taiwan New cases: 1,902 Deaths: 1,298
28 非何杰金氏淋巴瘤 非何杰金氏淋巴瘤 年齡別發生率, 96 年 年齡別死亡率, 96 年
29 組織形態 首次療程
30 何杰金氏淋巴瘤 何杰金氏淋巴瘤 年齡別發生率, 96 年 年齡別死亡率, 96 年
31 組織形態 首次療程
32 Treatment and prognosis 63 Indolent lymphomas Relatively good prognosis with a median survival as long as 10 years Usually are not curable in advanced clinical stages Early stage (stage I and stage II) can be effectively treated with radiation therapy alone
33 Aggressive lymphomas Shorter natural history Significant number of these patients can be cured with intensive combination chemotherapy Treatment Option Overview Radiation therapy : varies from 25 Gy to 50 Gy Combination chemotherapy Aggressive consolidation with marrow or stem cell support
34 Treatment Options for Advanced Low Grade Lymphoma Observation (watch and wait) Radiation Single agent therapy Combination chemotherapy Interferon Monoclonal antibodies Hematopoietic transplantation Antisense molecules Vaccines Targeted agents Treatment Option Overview Treatment of non Hodgkin lymphoma (NHL) depends on the histologic type and stage. Late effects of treatment of NHL : permanent sterility elevated risk for second primary cancers Left ventricular dysfunction Myelodysplastic syndrome and acute myelogenous leukemia
35 Survival Probability Evolving Standards of Care in Non-Hodgkin s Lymphoma clinicaloptions.com/oncology CHOP ± Rituximab in DLBCL: 7-Yr Survival Results (GELA LNH-98.5 Study) P =.0004 OS (N = 399) Parameter, % Yrs CHOP R-CHOP Low Risk High Risk Age, < 70 vs 70 yrs LDH, NI vs > NI * Stage, I/II vs III/IV Bone marrow, yes vs no * Tumor size, < 10 vs 10 cm β 2 -microglobulin, NI vs > NI * Serum albumin, 35 vs < 35 g/l *P <.05 (multivariate analysis). Coiffier B, et al. ASCO Abstract Prognosis Overall survival at 5 years is approximately 50% to 60% Aggressive NHL, 30% to 60% can be cured Vast majority of relapses occur in the first 2 years after therapy Asymptomatic patients with indolent forms of advanced NHL, treatment may be deferred until the patient becomes symptomatic as the disease progresses
36 The Follicular Lymphoma International Prognostic Index (FLIPI) FLIPI score used to predict outcomes of therapy based on adding number of risk factors (each factor = 1 point) LDH > ULN Older than 60 yrs of age > 4 involved nodal sites Ann Arbor stage III/IV disease Hb < 12 g/l FLIPI Risk Group Risk Factors, n Patients, % 5-Yr OS, % 10-Yr OS, % Relative Risk Low Intermediate 2 37 Solal Céligny P, et al. Blood. 2004;104: The High American Society of 3Hematology DLBCL: Prognostic Factors Risk Group Patients (all ages) Risk Factors, n CR, % 5-Yr OS, % Low Low intermediate High intermediate High Patients 60 yrs of age or younger Low Low intermediate High intermediate High International *Prognostic for NHL patients Prognosis older Factors than Project. 60 yrs of N Engl J Med. 1993;329: age only Adverse risk factors correlated with response to chemotherapy and survival Older than 60 yrs of age LDH > normal PS 2 Ann Arbor stage III/IV Extranodal involvement > 1 site*
37 Clinical Advances and Practical Applications in Lymphoma clinicaloptions.com/oncology OS in PTCL by IPI Score Proportion Remaining Alive Yrs IPI Score Censor Fail Total Media 0/ / Vose J, et al. J Clin Oncol. 2008;26: Reprinted with permission American Society of Clinical Oncology. All rights reserved Summary Heterogeneous group of lymphoproliferative malignancies Usually originates in lymphoid tissues and can spread to other organs Far greater predilection to disseminate to extranodal sites
38 Thank you for your attention! Questions?
2010 Hematopoietic and Lymphoid ICD-O Codes - Alphabetical List THIS TABLE REPLACES ALL ICD-O-3 Codes
Acute basophilic leukemia 9870/3 Acute biphenotypic leukemia [OBS] 9805/3 Acute erythroid leukemia 9840/3 Acute megakaryoblastic leukemia 9910/3 Acute monoblastic and monocytic leukemia 9891/3 Acute myeloid
More information2012 Hematopoietic and Lymphoid ICD-O Codes - Numerical List THIS TABLE REPLACES ALL ICD-O-3 Codes
Malignant lymphoma, NOS 9590/3 Non-Hodgkin lymphoma, NOS 9591/3 B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma 9596/3 Primary
More informationCombinations of morphology codes of haematological malignancies (HM) referring to the same tumour or to a potential transformation
Major subgroups according to the World Health Organisation (WHO) Classification Myeloproliferative neoplasms (MPN) Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or
More informationLymphoma/CLL 101: Know your Subtype. Dr. David Macdonald Hematologist, The Ottawa Hospital
Lymphoma/CLL 101: Know your Subtype Dr. David Macdonald Hematologist, The Ottawa Hospital Function of the Lymph System Lymph Node Lymphocytes B-cells develop in the bone marrow and influence the immune
More informationBone Marrow. Procedures Blood Film Aspirate, Cell Block Trephine Biopsy, Touch Imprint
Bone Marrow Protocol applies to acute leukemias, myelodysplastic syndromes, myeloproliferative disorders, chronic lymphoproliferative disorders, malignant lymphomas, plasma cell dyscrasias, histiocytic
More informationDuring past decades, because of the lack of knowledge
Staging and Classification of Lymphoma Ping Lu, MD In 2004, new cases of non-hodgkin s in the United States were estimated at 54,370, representing 4% of all cancers and resulting 4% of all cancer deaths,
More informationLarge cell immunoblastic Diffuse histiocytic (DHL) Lymphoblastic lymphoma Diffuse lymphoblastic Small non cleaved cell Burkitt s Non- Burkitt s
Non Hodgkin s Lymphoma Introduction 6th most common cause of cancer death in United States. Increasing in incidence and mortality. Since 1970, the incidence of has almost doubled. Overview The types of
More informationWHO Classification. B-cell chronic lymphocytic leukemia/small T-cell granular lymphocytic leukemia
Blood Malignancies-II Prof. Dr. Herman Hariman, a Ph.D, SpPK (KH). Prof. Dr. Adikoesoema Aman, SpPK (KH) Dept. of Clinical Pathology, School of Medicine, University of North Sumatra WHO classification
More informationChanges to the Hematopoietic and Lymphoid Neoplasm Coding Manual
Changes to the Hematopoietic and Lymphoid Neoplasm Coding Manual KCR 2018 SPRING TRAINING 2018 Hematopoietic Database Updates Updates were done to the Hematopoietic Database based on the WHO Hematopoietic
More informationClinical Policy: Bendamustine (Bendeka, Treanda) Reference Number: PA.CP.PHAR.307
Clinical Policy: (Bendeka, Treanda) Reference Number: PA.CP.PHAR.307 Effective Date: 01/18 Last Review Date: 11/17 Coding Implications Revision Log Description The intent of the criteria is to ensure that
More informationIntroduction: The Revised (4 th Edition) World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissues
Society for Hematopathology Scientific Symposium USCAP Companion Meeting, Boston, MA March 8, 2009 Boston, MA Steven H. Swerdlow and James Vardiman, Moderators Introduction: The Revised (4 th Edition)
More informationNon-Hodgkin Lymphoma. Protocol applies to non-hodgkin lymphoma involving any organ system except the gastrointestinal tract.
Non-Hodgkin Lymphoma Protocol applies to non-hodgkin lymphoma involving any organ system except the gastrointestinal tract. Protocol revision date: January 2005 No AJCC/UICC staging system Procedures Cytology
More informationChange Summary - Form 2018 (R3) 1 of 12
Summary - Form 2018 (R3) 1 of 12 Form Question Number (r3) Type Description New Text Previous Text Today's date was removed 2018 N/A Today's Date Removed from Key Fields 2018 N/A HCT Type 2018 N/A Product
More informationHepatic Lymphoma Diagnosis An Algorithmic Approach
Hepatic Lymphoma Diagnosis An Algorithmic Approach Ryan M. Gill, M.D., Ph.D. University of California, San Francisco PLEASE TURN OFF YOUR CELL PHONES Disclosure of Relevant Financial Relationships USCAP
More informationClassifications of lymphomas
Classifications of lymphomas Lukes and Collins Kiel classification Working formulation REAL classification (1994) WHO classification (2000) WHO CLASSIFICATIONF OF NEOPLASMS HAEMATOPETIC AND LYMPHOID TISSUES
More informationNon-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL)
Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL) Lymphoid Neoplasms: 1- non-hodgkin lymphomas (NHLs) 2- Hodgkin lymphoma 3- plasma cell neoplasms Non-Hodgkin lymphomas (NHLs) Acute Lymphoblastic Leukemia/Lymphoma
More informationContents. vii. Preface... Acknowledgments... v xiii
Contents Preface... Acknowledgments... v xiii SECTION I 1. Introduction... 3 Knowledge-Based Diagnosis... 4 Systematic Examination of the Lymph Node... 7 Cell Type Identification... 9 Cell Size and Cellularity...
More informationSmall B-cell (Histologically Low Grade) Lymphoma
Frequency of Lymphoid Neoplasms Small B-cell (Histologically Low Grade) Lymphoma Stephen Hamilton-Dutoit Institute of Pathology Aarhus University Hospital B-cell neoplasms 88% Diffuse large B-cell lymphoma
More informationChanges to the Hematopoietic and Lymphoid Neoplasm Coding Manual
Changes to the Hematopoietic and Lymphoid Neoplasm Coding Manual KCR 2018 SPRING TRAINING 2018 Hematopoietic Database Updates Updates were done to the Hematopoietic Database based on the WHO Hematopoietic
More informationLymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC
Lymphoma: What You Need to Know Richard van der Jagt MD, FRCPC Overview Concepts, classification, biology Epidemiology Clinical presentation Diagnosis Staging Three important types of lymphoma Conceptualizing
More informationIntegrated Hematopathology. Morphology and FCI with IHC
Integrated Hematopathology Morphology and FCI with IHC FrontMatter.indd i 9/6/2009 9:30:12 PM FrontMatter.indd ii 9/6/2009 9:30:18 PM Integrated Hematopathology Morphology and FCI with IHC Cherie H Dunphy,
More informationLymphoma: The Basics. Dr. Douglas Stewart
Lymphoma: The Basics Dr. Douglas Stewart Objectives What is lymphoma? How common is it? Why does it occur? How do you diagnose it? How do you manage it? How do you follow patients after treatment? What
More informationImmunopathology of Lymphoma
Immunopathology of Lymphoma Noraidah Masir MBBCh, M.Med (Pathology), D.Phil. Department of Pathology Faculty of Medicine Universiti Kebangsaan Malaysia Lymphoma classification has been challenging to pathologists.
More informationHematopoietic Stem-Cell Transplantation for Non-Hodgkin Lymphomas. Original Policy Date
MP 7.03.13 Hematopoietic Stem-Cell Transplantation for Non-Hodgkin Lymphomas Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with literature search/12/2013
More informationBurkitt lymphoma. Sporadic Endemic in Africa associated with EBV Translocations involving MYC gene on chromosome 8
Heme 8 Burkitt lymphoma Sporadic Endemic in Africa associated with EBV Translocations involving MYC gene on chromosome 8 Most common is t(8;14) Believed to be the fastest growing tumor in humans!!!! Morphology
More informationHematopoietic Stem-Cell & Clinical Coverage Policy No: 11A-11 Bone Marrow Transplantation Amended Date: March 1, 2017 For Non-Hodgkin s Lymphoma
Hematopoietic Stem-Cell & Clinical Coverage Policy No: 11A-11 Bone Marrow Transplantation Amended Date: March 1, 2017 For Non-Hodgkin s Lymphoma Table of Contents 1.0 Description of the Procedure, Product,
More informationMANAGEMENT OF LYMPHOMAS
MANAGEMENT OF LYMPHOMAS Challenges & Recommendations F. Chite Asirwa, MD. Internal Medicine Physician Medical Oncologist & Hematologist Director-AMPATH Oncology & Hematology @Kenya Physicians Association
More informationIndolent Lymphomas. Dr. Melissa Toupin The Ottawa Hospital
Indolent Lymphomas Dr. Melissa Toupin The Ottawa Hospital What does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with
More informationHematopoietic Cell Transplantation for Non-Hodgkin's Lymphomas
Medical Policy Manual Transplant, Policy No. 45.23 Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphomas Next Review: September 2018 Last Review: December 2017 Effective: January 1, 2018 IMPORTANT
More informationClinical Policy: Bendamustine (Bendeka, Treanda) Reference Number: CP.PHAR.307
Clinical Policy: (Bendeka, Treanda) Reference Number: CP.PHAR.307 Effective Date: 02/17 Last Review Date: 02/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important
More informationClassification of Hematologic Malignancies. Patricia Aoun MD MPH
Classification of Hematologic Malignancies Patricia Aoun MD MPH Objectives Know the basic principles of the current classification system for hematopoietic and lymphoid malignancies Understand the differences
More informationOverview of Cutaneous Lymphomas: Diagnosis and Staging. Lauren C. Pinter-Brown MD, FACP Health Sciences Professor of Medicine and Dermatology
Overview of Cutaneous Lymphomas: Diagnosis and Staging Lauren C. Pinter-Brown MD, FACP Health Sciences Professor of Medicine and Dermatology Definition of Lymphoma A cancer or malignancy that comes from
More informationAggressive B-cell Lymphoma 2013
Aggressive B-cell Lymphoma 2013 Diffuse Large B-Cell Lymphoma Burkitt Lymphoblastic lymphoma Gray zone Intermediate DLBCL/HL Intermediate BL/DLBCL Diffuse Large B-cell lymphoma Common morphology: diffuse
More informationHematopoietic Stem-Cell Transplantation for Non-Hodgkin s Lymphomas
Hematopoietic Stem-Cell Transplantation for Non-Hodgkin s Lymphomas Policy Number: 8.01.20 Last Review: 7/2014 Origination: 7/2002 Next Review: 7/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationPearls and pitfalls in interpretation of lymphoid lesions in needle biopsies
Pearls and pitfalls in interpretation of lymphoid lesions in needle biopsies Megan S. Lim MD PhD University of Pennsylvania October 8, 2018 Objectives To understand how the trend toward less invasive lymph
More informationT-cell Lymphomas Biology and Management
T-cell Lymphomas Biology and Management March-27-2017 Outline Epidemiology Initial Work-up International Prognostic Index Treatment of Diffuse Large B-cell Lymphoma: -Limited Stage -Advanced Stage Frontline:
More informationLymphatic system component
Introduction Lymphatic system component Statistics Overview Lymphoma Non Hodgkin s Lymphoma Non- Hodgkin's is a type of cancer that originates in the lymphatic system. It is estimated to be the sixth most
More informationProtocol for the Examination of Specimens From Patients With Non-Hodgkin Lymphoma/Lymphoid Neoplasms
Protocol for the Examination of Specimens From Patients With Non-Hodgkin Lymphoma/Lymphoid Neoplasms Version: Protocol Posting Date: October 2013 This protocol is NOT required for accreditation purposes
More information88-year-old Female with Lymphadenopathy. Faizi Ali, MD
88-year-old Female with Lymphadenopathy Faizi Ali, MD Clinical History A 88-year-old caucasian female presented to our hospital with the complaints of nausea, vomiting,diarrhea, shortness of breath and
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplant for Non-Hodgkin Lymphomas File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplant_for_non_hodgkin_lymphomas
More informationUnderstanding your diagnosis. Dr Graham Collins Consultant Haemtologist Oxford University Hospitals
Understanding your diagnosis Dr Graham Collins Consultant Haemtologist Oxford University Hospitals Common questions I get asked What is lymphoma? What subtype do I have and what does that mean? What are
More informationIndolent Lymphomas: Current. Dr. Laurie Sehn
Indolent Lymphomas: Current Dr. Laurie Sehn Why does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with current standard
More informationMichi Shinohara MD Associate Professor University of Washington/Seattle Cancer Care Alliance Dermatology, Dermatopathology
Michi Shinohara MD Associate Professor University of Washington/Seattle Cancer Care Alliance Dermatology, Dermatopathology Agenda Overview of cutaneous T and B- cell lymphomas Diagnosis, Staging, Prognosis
More informationHematopoietic Stem-Cell Transplantation for Non-Hodgkin Lymphomas
Hematopoietic Stem-Cell Transplantation for Non-Hodgkin Lymphomas Policy Number: Original Effective Date: MM.07.018 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO 03/27/2015 Section:
More information7 Omar Abu Reesh. Dr. Ahmad Mansour Dr. Ahmad Mansour
7 Omar Abu Reesh Dr. Ahmad Mansour Dr. Ahmad Mansour -Leukemia: neoplastic leukocytes circulating in the peripheral bloodstream. -Lymphoma: a neoplastic process in the lymph nodes, spleen or other lymphatic
More informationAggressive Lymphomas - Current. Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre
Aggressive Lymphomas - Current Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre Conflicts of interest I have no conflicts of interest to declare Outline What does aggressive lymphoma
More informationDifferential diagnosis of hematolymphoid tumors composed of medium-sized cells. Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital
Differential diagnosis of hematolymphoid tumors composed of medium-sized cells Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital Lymphoma classification Lymphoma diagnosis starts with morphologic
More informationPlasma cell myeloma (multiple myeloma)
Plasma cell myeloma (multiple myeloma) Common lymphoid neoplasm, present at old age (70 years average) Remember: plasma cells are terminally differentiated B-lymphocytes that produces antibodies. B-cells
More informationMedical Policy Manual. Date of Origin: May Topic: Hematopoietic Stem-Cell Transplantation for Non- Hodgkin Lymphomas
Medical Policy Manual Topic: Hematopoietic Stem-Cell Transplantation for Non- Hodgkin Lymphomas Section: Transplant Policy No: 45.23 Date of Origin: May 2010 Last Reviewed Date: September 2013 Effective
More informationLYMPHOMAS an overview of some subtypes of NHLs
One of the confusing aspects of the lymphoid neoplasms concerns the use of the descriptive terms "leukemia" and "lymphoma." LYMPHOMAS an overview of some subtypes of NHLs Leukemia is used for lymphoid
More informationNON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.
More informationNon-Hodgkin s Lymphomas Version
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Non-Hodgkin s Lymphomas Version 2.2015 NCCN.org Continue Use of Immunophenotyping/ Genetic Testing in Differential Diagnosis of Mature B-Cell
More informationThe next lymphoma classification Luca Mazzucchelli Istituto cantonale di patologia, Locarno
Evolution of classification The next classification Luca Mazzucchelli Istituto cantonale di patologia, Locarno The Lymphoma Forum of Excellence, Bellinzona, January 2011 Rappaport Lukes and Collins (immunophenotype)
More informationCorrigenda. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (revised 4th edition): corrections made in second print run
Corrigenda WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (revised 4th edition): corrections made in second print run In addition to corrections of minor typographical errors, corrections
More informationConflict of Interest Disclosure Form NAME :James O. Armitage, M.D AFFILIATION: University of Nebraska Medical Center
What Is Personalized Medicine For Patients With Lymphoma? Conflict of Interest Disclosure Form NAME :James O. Armitage, M.D AFFILIATION: University of Nebraska Medical Center DISCLOSURE I have no potential
More informationLEUKAEMIA and LYMPHOMA. Dr Mubarak Abdelrahman Assistant Professor Jazan University
LEUKAEMIA and LYMPHOMA Dr Mubarak Abdelrahman Assistant Professor Jazan University OBJECTIVES Identify etiology and epidemiology for leukemia and lymphoma. Discuss common types of leukemia. Distinguish
More informationNon-Hodgkin lymphoma
Non-Hodgkin lymphoma Non-Hodgkin s lymphoma Definition: - clonal tumours of mature and immature B cells, T cells or NK cells - highly heterogeneous, both histologically and clinically Non-Hodgkin lymphoma
More informationLymphoid Neoplasms. Sylvie Freeman Department of Clinical Immunology, University of Birmingham
Lymphoid Neoplasms Sylvie Freeman Department of Clinical Immunology, University of Birmingham Incidence of Haematological Malignancies UK2001 (CRUK) Malignancy New Cases All Cancers 271,000 Leukaemia 6,760
More informationProtocol for the Examination of Specimens From Patients With Non-Hodgkin Lymphoma/Lymphoid Neoplasms
Protocol for the Examination of Specimens From Patients With Non-Hodgkin Lymphoma/Lymphoid Neoplasms Protocol applies to non-hodgkin lymphoma/lymphoid neoplasms involving any site except the ocular adnexa,
More informationAggressive B-Cell Lymphomas
Aggressive B-cell Lymphomas Aggressive B-Cell Lymphomas Stephen Hamilton Dutoit Institute of Pathology Aarhus Kommunehospital B-lymphoblastic lymphoma Diffuse large cell lymphoma, NOS T-cell / histiocyte-rich;
More information3.1 Introduction. It is emphasised that not all tests are necessarily required in every case. 3.2 Taxonomic structure
CHAPTER 3 CLASSIFICATION 3.1 Introduction Accurate diagnosis underpins lymphoma management. Historically, competing lymphoma classifications have been a source of frustration to pathologists, clinicians
More informationAggressive NHL and Hodgkin Lymphoma. Dr. Carolyn Faught November 10, 2017
Aggressive NHL and Hodgkin Lymphoma Dr. Carolyn Faught November 10, 2017 What does aggressive mean? Shorter duration of symptoms Generally need treatment at time of diagnosis Immediate, few days, few weeks
More informationPrimary Cutaneous CD30-Positive T-cell Lymphoproliferative Disorders
Primary Cutaneous CD30-Positive T-cell Lymphoproliferative Disorders Definition A spectrum of related conditions originating from transformed or activated CD30-positive T-lymphocytes May coexist in individual
More information3/23/2017. Disclosure of Relevant Financial Relationships. Pitfalls in Immunohistochemistry in Hematopathology: CD20 and CD3 Can Let Me Down?!
Pitfalls in Immunohistochemistry in Hematopathology: CD20 and CD3 Can Let Me Down?! Judith A. Ferry Massachusetts General Hospital Disclosure of Relevant Financial Relationships USCAP requires that all
More informationHigh grade B-cell lymphomas (HGBL): Altered terminology in the 2016 WHO Classification (Update of the 4 th Edition) and practical issues Xiao-Qiu Li,
High grade B-cell lymphomas (HGBL): Altered terminology in the 2016 WHO Classification (Update of the 4 th Edition) and practical issues Xiao-Qiu Li, M.D., Ph.D. Fudan University Shanghai Cancer Center
More information2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes
2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes Lauren R. Teras, PhD 1 ; Carol E. DeSantis, MPH 2 ; James R. Cerhan, MD, PhD 3 ; Lindsay M. Morton, PhD 4 ; Ahmedin Jemal, DVM,
More informationHematology Page 1 of 8
Hematology Page 1 of 8 Hematology Major Category Code Headings Revised 12/17 1 Basic methodology and test armamentarium 20000 2 Normal hematopoiesis & hemostasis 20100 3 RBC disorders, non-neoplastic 20340
More informationMolecular Pathology of Lymphoma (Part 1) Rex K.H. Au-Yeung Department of Pathology, HKU
Molecular Pathology of Lymphoma (Part 1) Rex K.H. Au-Yeung Department of Pathology, HKU Lecture outline Time 10:00 11:00 11:15 12:10 12:20 13:15 Content Introduction to lymphoma Review of lymphocyte biology
More informationCOPYRIGHTED MATERIAL. Introduction CHAPTER 1. Examination of p atients. Classification of c utaneous l ymphomas. Staging i nvestigations
CHAPTER 1 Introduction Primary cutaneous lymphomas represent distinct clinical and histopathologic subtypes of extranodal lymphomas. They can be defined as neoplasms of the immune system, characterized
More informationProtocol for the Examination of Specimens From Patients With Hematopoietic Neoplasms Involving the Bone Marrow
Protocol for the Examination of Specimens From Patients With Hematopoietic Neoplasms Involving the Bone Marrow Based on AJCC/UICC TNM, 7 th Edition Protocol web posting date: February 1, 2011 Procedures
More informationHarmesh Naik, MD. GME Presentation to Family Practice Residents October 16, 2013.
Harmesh Naik, MD. GME Presentation to Family Practice Residents October 16, 2013. Lymphoma: Lympho-proliferative disorders arising from lymphocytes Heterogeneous group of disorders Differing patterns of
More informationBone Marrow. Procedures Blood Film Aspirate, Cell Block Trephine Biopsy, Touch Imprint
Bone Marrow Protocol applies to acute leukemias, myelodysplastic syndromes, myeloproliferative disorders, chronic lymphoproliferative disorders, malignant lymphomas, plasma cell dyscrasias, histiocytic
More informationDefined lymphoma entities in the current WHO classification
Defined lymphoma entities in the current WHO classification Luca Mazzucchelli Istituto cantonale di patologia, Locarno Bellinzona, January 29-31, 2016 Evolution of lymphoma classification Rappaport Lukes
More informationBACKGROUND INFORMATION ON NON-HODGKIN S LYMPHOMA
BACKGROUND INFORMATION ON NON-HODGKIN S LYMPHOMA General Non-Hodgkin s lymphomas (NHLs) encompass several unique malignant lymphoid disease entities that vary in clinical behavior, morphologic appearance,
More informationReviewing the ICD-10 classification of haematological neoplasms on its way to ICD-11
WHO-FIC NETWORK MEETING Tokyo, Japan haematological neoplasms on its way to ICD-11 Ulrich Vogel, Robert Jakob, Michael Schopen, Harald Stein, Stefan Krause Abstract: haematological neoplasms on its way
More informationNAACCR Webinar Series 1
COLLECTING CANCER DATA: HEMATOPOIETIC AND LYMPHOID NEOPLASMS Jim Hofferkamp, CTR (jhofferkam@naaccr.org) Shannon Vann, CTR (svann@naaccr.org) Q&A Please submit all questions concerning webinar content
More informationBone Marrow. Procedures Blood Film Aspirate, Cell Block Trephine Biopsy, Touch Imprint
Bone Marrow Protocol applies to acute leukemias, myelodysplastic syndromes, myeloproliferative disorders, chronic lymphoproliferative disorders, malignant lymphomas, plasma cell dyscrasias, histiocytic
More informationSupplementary Appendix to manuscript submitted by Trappe, R.U. et al:
Supplementary Appendix to manuscript submitted by Trappe, R.U. et al: Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful
More informationMyeloid malignancies Chronic myeloid disorders
Myeloid malignancies Chronic myeloid disorders Myeloproliferative neoplasms (MPN) Mastocytosis / Mast cell diseases Myeloid/lymphoid neoplasms with eosinophilia and gene rearrangement Myelodysplastic/myeloproliferative
More informationAggressive B-cell Lymphomas
Neoplastic Hematopathology Update 2018 Aggressive B-cell Lymphomas Raju K. Pillai City of Hope National Medical Center I do not have any disclosures Disclosures Outline New entities and changes in WHO
More informationUNIVERSITÀ DI PISA FACOLTÀ DI MEDICINA E CHIRURGIA TESI DI LAUREA
UNIVERSITÀ DI PISA FACOLTÀ DI MEDICINA E CHIRURGIA Corso di Laurea Specialistica in Medicina e Chirurgia TESI DI LAUREA How to treat Splenic Marginal Zone Lymphoma (SMZL) in patients unfit for surgery
More informationSH/EAHP Workshop 2011 Los Angeles, California, USA
SH/EAHP Workshop 2011 Los Angeles, California, USA October 27-29, 2011 Session 3 Non-Mycosis Fungoides CTCL Patty Jansen & Rein Willemze Introduction Submitted: 101 cases + 7 cases group 1: 108 Deactivated
More informationHODGKIN LYMPHOMA DR. ALEJANDRA ZARATE OSORNO HOSPITAL ESPAÑOL DE MEXICO
HODGKIN LYMPHOMA DR. ALEJANDRA ZARATE OSORNO HOSPITAL ESPAÑOL DE MEXICO HODGKIN LYMPHOMA CLASSIFICATION Lukes & Butler Rye WHO-2016 Linphocytic and/or histiocytic Nodular & diffuse Nodular Sclerosis Lymphocyte
More informationImmunohistochemical classification of haematolymphoid tumours. Stephen Hamilton-Dutoit Institute of Pathology Aarhus University Hospital
Immunohistochemical classification of haematolymphoid tumours Stephen Hamilton-Dutoit Institute of Pathology Aarhus University Hospital Malignant lymphoproliferative diseases What are they? Haematolymphoid
More informationPathology #07. Hussein Al-Sa di. Dr. Sohaib Al-Khatib. Mature B-Cell Neoplasm. 0 P a g e
Pathology #07 Mature B-Cell Neoplasm Hussein Al-Sa di Dr. Sohaib Al-Khatib 0 P a g e Thursday 18/2/2016 Our lecture today (with the next 2 lectures) will be about lymphoid tumors This is a little bit long
More informationMany of the hematolymphoid disorders are derived
REVIEW ARTICLE Practical Immunohistochemistry in Hematopathology: A Review of Useful Antibodies for Diagnosis Ji Lu, MD and Karen L. Chang, MD Abstract: This review article offers some useful panels of
More informationFrom Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology. Songlin Zhang, MD, PhD LSUHSC-Shreveport
From Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology Songlin Zhang, MD, PhD LSUHSC-Shreveport I have no Conflict of Interest. FNA on Lymphoproliferative
More informationEPIDEMIOLOGY AND SPECIFIC RISK FACTORS FOR MALIGNANT LYMPHOMA IN THE SINGAPORE POPULATION
EPIDEMIOLOGY AND SPECIFIC RISK FACTORS FOR MALIGNANT LYMPHOMA IN THE SINGAPORE POPULATION WONG KIN YOKE NATIONAL UNIVERSITY OF SINGAPORE 2012 EPIDEMIOLOGY AND SPECIFIC RISK FACTORS FOR MALIGNANT LYMPHOMA
More informationDETERMINATION OF A LYMPHOID PROCESS
Chapter 2 Applications of Touch Preparation Cytology to Intraoperative Consultations: Lymph Nodes and Extranodal Tissues for Evaluation of Hematolymphoid Disorders INTRODUCTION As discussed in Chap. 1,
More informationC r h ist s op o h p e h r e R. R F l F ow o er e s, s M D, D M S
1 Christopher R. Flowers, MD, MS Associate Professor of Hematology and Medical Oncology Winship Cancer Institute Emory University School of Medicine Atlanta, Georgia 2 1 Anyone can get blood cancer One
More informationThe College of American Pathologists offers these protocols
Strategies for Laboratory and Patient Management Protocol for the Examination of Specimens From Patients With Hematopoietic Neoplasms of the Bone Marrow A Basis for Checklists LoAnn C. Peterson, MD; Steven
More information10/31/2017. Immunodeficiencies. Outline. Discuss EBV. Non-destructive Polymorphic Monomorphic Therapies Challenges
I have no financial disclosures Joo Y. Song, MD Assistant Professor of Clinical Pathology City of Hope National Medical Center Immunodeficiencies Outline Transplant Congenital Autoimmunity T-cell/immune
More informationCommon Problem Areas. WHO Classification. Defines separate diseases (entities) with their CLINICAL AGGRESSIVENESS LOW GRADE / HIGH GRADE
WHO Classification Defines separate diseases (entities) with their CLINICAL AGGRESSIVENESS REVIEW OF MOST COMMON LYMPHOMA ENTITIES Dr Stefan Dojcinov LOW GRADE / HIGH GRADE (June 2014) The Non-Hodgkin
More informationAggressive B-cell lymphomas and gene expression profiling towards individualized therapy?
Aggressive B-cell lymphomas and gene expression profiling towards individualized therapy? Andreas Rosenwald Institute of Pathology, University of Würzburg, Germany Barcelona, June 18, 2010 NEW WHO CLASSIFICATION
More informationLymphoma and Myeloma Kris3ne Kra4s, M.D.
Lymphoma and Myeloma Kris3ne Kra4s, M.D. Hematologic Malignancies Leukemia Malignancy of hematopoie3c cells Starts in bone marrow, can spread to blood, nodes Myeloid or lymphoid Acute or chronic Lymphoma
More information11/2/2017. Immunodeficiencies. Joo Y. Song, MD Assistant Professor of Clinical Pathology. I have no financial disclosures.
I have no financial disclosures Joo Y. Song, MD Assistant Professor of Clinical Pathology City of Hope National Medical Center Immunodeficiencies Transplant Autoimmunity Drugs T-cell dysfunction (Age,
More informationHead and Neck: DLBCL
Head and Neck: DLBCL Nikhil G. Thaker Chelsea C. Pinnix Valerie K. Reed Bouthaina S. Dabaja Department of Radiation Oncology MD Anderson Cancer Center Case 60 yo male Presented with right cervical LAD
More informationQ&A Session Collecting Cancer Data: Hematopoietic and Lymphoid Neoplasms Thursday, November 6, 2014
Q&A Session Collecting Cancer Data: Hematopoietic and Lymphoid Neoplasms Thursday, November 6, 2014 Q: If polycythemia ruba vera (PRV) or essential thrombocythemia (ET) is diagnosed by peripheral smear,
More information